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8 Abstract 
Tumour necrosis factor (TNF) is potent pro-inflammatory and anti-viral cytokine, acting 
via two cellular receptors, TNFR1 and TNFR2 that induces apoptosis and inflammation. 
Poxviruses encode homologues of TNF-receptors (viral TNFRs) that independently 
interact with both TNF, and simultaneously with cellular TNFRs, to subvert TNF-induced 
anti-viral apoptosis. The vTNFRs are expressed during poxvirus infection and are 
considered as bona fide virulence factors. The recently discovery of a “Pre-ligand 
Assembly Domain (PLAD)” within the N-terminus of the cellular TNFRs is shown to be 
required for receptor trimerisation and efficient cell death signalling. Whilst it has 
previously shown that the rabbit-trophic Myxoma (MYX) viral TNFR also contains a PLAD 
required for viral TNFR:cellular TNFR interactions, little is known about the human-
trophic poxvirus TNFRs, nor physical characteristics of the interactions of vTNFRs and 
cellular TNFRs. 
 
To assess the importance of the PLAD domain in TNFR structure, function and viral 
subversion of TNFRs, this study focused on naturally occurring mutations in the TNFR 
PLAD domain, that occur in transient periodic fevers (TRAPS) – a clinical syndrome of 
febrile attacks of inflammation. TRAPS PLAD domain mutations were generated in a 
TNFR1-YFP in plasmids by site-directed mutagenesis and cloning. WT and TRAPS mutant 
TNFR1 constructs were transfected into U20S cells and TNFR1 location was determined 
by confocal microscopy. Neither WT TNFR1 nor TRAPS TNFRs were unable to be 
detected at the cell surface by both widefield and confocal microscopy despite published 
data on surface expression of WT TNFR1. WT TNFR1-YFP fusion proteins were found to 
be expressed within endocytic vesicles known as receptosomes and also as aggregates 
xxi 
 
in a membranous structure resembling Golgi/ER. In addition it was found that TRAPS 
mutations in particular those affecting critical amino acids such as cysteines in 
disulphide bonds, display reduced TNFR-induced cell death as determined by flow 
cytometry. 
 
To better understand the biology of the vTNFR association with cellular TNFRs, 
and with WHO Smallpox committee approval, the human tropic poxviral TNFRs from 
Variola (Smallpox) (VAR) and Monkeypox (MPV) were synthesised and cloned as 
CFP/YFP and MycHis expression plasmids. Using multi-colour flow cytometry we have 
shown that, like the MYXT2 vTNFR, VARG4R and MPVJ2R TNFRs are potent intracellular 
inhibitors of TNFR1-induced cell death. As each vTNFR was able to inhibit TNFR-induced 
cell death, an assay was developed by flow cytometry to measure the intracellular 
abundance of the vTNFRs in the presence of cellular TNFR overexpression. MYXT2 was 
found to increase in intracellular abundance however for unknown reasons VARG4R and 
MPVJ2R did not convincingly increase in abundance. A structure for each of the vTNFRs 
was then attempted to be determined by X-ray crystallography, however bacterial 
expression of the both the cellular TNFRs and viral TNFRs proteins were unable to be 
obtained. 
 
Lastly to determine the structural orientations and conformations of cellular 
vTNFR interactions, a method of fluorescence resonance energy transfer (FRET) was 
established by flow cytometry. Using the generated C-terminal fusion -CFP and -YFP 
TNFRs, interactions were assessed between each of the cellular and vTNFRs. It was 
found that in addition to the reduced cell death TRAPS TNFRs when expressed with WT 
TNFR1, TRAPS mutations also cause reduced FRET possibly due to altered conformations 
xxii 
 
in the receptor. Again mutations affecting more critical structural amino acids were 
found to have a more dramatic effect. Moreover differences were observed between 
mutations in distribution of FRET histograms further indicating altered network 
formations of higher order complexes. Next the FRET method was used to assess 
interactions between each of the vTNFRs with WT human TNFRs as well as with 
themselves and other vTNFRs. However no FRET was detectable between each of the 
molecules despite evidence of MYXT2 associating with human TNFR1 and TNFR2. Thus 
Comparative homology modelling and automated docking simulations were performed 
to explain possible orientations of the interactions tested in FRET. These data suggest 
that the interactions of vTNFRs with cellular TNFRs may possibly occur in a C-N anti-
parallel orientation and not the previously predicted PLAD-PLAD interactions. 
 
Taken together, these data further our understanding of basic TNFR biology as 
well as for the first time characterise an entire panel of PLAD TRAPS mutations. It also 
furthers the characterisation of the very limited evidence of vTNFR subversion of TNFRs 
for the human trophic viral proteins VARG4R and MPVJ2R. Overall these results show 
the importance of PLAD interactions to TNFR biology and a possible new avenue in which 
TNFR signalling may be exploited in the development of new therapeutics.
